Suggestions
Andrew Hindman
Biotech Entrepreneur // Non-Profit Work
Andrew Hindman is a seasoned biotech executive with a proven track record of establishing companies, enhancing shareholder value, and providing healthcare solutions to patients and caregivers. With close to 30 years of experience, Andrew has been involved in a range of high-value transactions including M&A deals, BD Partnerships, Equity/Debt financings, and Royalty Monetization/securitizations totaling over $30 billion.
He possesses a strong set of financial, strategic, and operational skills specifically tailored to the drug development and commercialization sector. Andrew holds an MBA in Finance from Columbia Business School, a BA in Biochemistry and Economics from Wesleyan University, and has also completed Executive Education in Leadership and Strategy in Pharma & Biotech at Harvard Business School.
Throughout his career, Andrew has held pivotal roles in various organizations, including positions such as Biotech Entrepreneur at NewCo, Chief Financial Officer at Theravance Biopharma US, Inc., Chief Business Officer at Acorda Therapeutics, Inc., Board Member at Biotechnology Industry Organization, President and Chief Executive Officer at Tobira Therapeutics, Senior Vice President, Corporate Development at Nodality Inc., Vice President, Corporate Development at Onyx Pharmaceuticals, Senior Director at Gilead Sciences, and Associate-Healthcare Investment Banking at J.P. Morgan.
His extensive educational background combined with his diverse professional experience has equipped Andrew Hindman with a unique blend of expertise in the biotech industry, making him a valuable asset in driving innovation, growth, and success in the healthcare sector.
Highlights
I’m happy to share that I’m starting a new position as Rider at The Tour 21!
Saddened this morning to awake to news on #TBPH's 3rd round of restructuring in under 16 months. Best wishes to all TBPH Team members who find themselves charting difficult times, managing one's own sanity amidst uncertainty about their next career chapter, and experiencing deep sadness for not being able to work with those TBPH Team members who are staying on to realize the full value of TRELEGY, YUPELRI, and TBPH's other financial/royalty/R&D assets. In fact, TBPH's greatest asset of all is: TBPH's WONDERFULLY TALENTED & INSPIRING PEOPLE.
Special Note to all TBPH LinkedIn friends: Feel free to reach out to me anytime to discuss the state of the current biopharma hiring market. The reality is that truly talented, team-oriented and tenacious individuals WILL ALWAYS FIND JOBS IN BIOPHARMA. Demand vastly exceeds supply for those who dedicate themselves to changing the world through science and Medicines that Make a Difference!
https://lnkd.in/gfzwqYmm
ONWARD! AAH PS: if you've made it this far, and would be interested in supporting my current "bicycle career chapter", please look into #TheTour21 or www.TheTour21.co.uk, and if you're feeling generous, please go https://lnkd.in/gsRc_-ut. // Thank you! in advance for your kindness and generosity!!!
#team #work #thankyou #cureleukemia #curecancer #tdf #tdf2023 #VivaLaFRANCE
